JP2023503852A - 感染症を処置するための低分子フーリン阻害剤 - Google Patents

感染症を処置するための低分子フーリン阻害剤 Download PDF

Info

Publication number
JP2023503852A
JP2023503852A JP2022527989A JP2022527989A JP2023503852A JP 2023503852 A JP2023503852 A JP 2023503852A JP 2022527989 A JP2022527989 A JP 2022527989A JP 2022527989 A JP2022527989 A JP 2022527989A JP 2023503852 A JP2023503852 A JP 2023503852A
Authority
JP
Japan
Prior art keywords
methyl
oxy
pyridin
dichlorophenyl
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022527989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503852A5 (https=
Inventor
ウィルコクソン，キース
マーパ，クラウディーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BP Asset V Inc
Original Assignee
BP Asset V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BP Asset V Inc filed Critical BP Asset V Inc
Publication of JP2023503852A publication Critical patent/JP2023503852A/ja
Publication of JP2023503852A5 publication Critical patent/JP2023503852A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022527989A 2019-11-12 2020-11-12 感染症を処置するための低分子フーリン阻害剤 Pending JP2023503852A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962934407P 2019-11-12 2019-11-12
US62/934,407 2019-11-12
PCT/US2020/060108 WO2021097009A1 (en) 2019-11-12 2020-11-12 Small molecule furin inhibitors for treating infectious diseases

Publications (2)

Publication Number Publication Date
JP2023503852A true JP2023503852A (ja) 2023-02-01
JP2023503852A5 JP2023503852A5 (https=) 2023-11-20

Family

ID=73793799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022527989A Pending JP2023503852A (ja) 2019-11-12 2020-11-12 感染症を処置するための低分子フーリン阻害剤

Country Status (8)

Country Link
US (1) US20230011571A1 (https=)
EP (1) EP4058021A1 (https=)
JP (1) JP2023503852A (https=)
KR (1) KR20220104744A (https=)
CN (1) CN114929220A (https=)
AU (1) AU2020382819A1 (https=)
CA (1) CA3157892A1 (https=)
WO (1) WO2021097009A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020022961A2 (pt) 2018-05-11 2021-02-17 Glaxosmithkline Intellectual Property Development Limited inibidores de furina
DE102023126563A1 (de) * 2023-09-28 2025-04-03 Philipps-Universität Marburg, Körperschaft des öffentlichen Rechts Hemmstoffe der Proproteinkonvertase Furin, Verfahren zu deren Herstellung und Verwendung

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014152716A1 (en) * 2013-03-15 2014-09-25 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
US20150051138A1 (en) * 2012-03-16 2015-02-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
JP2021523941A (ja) * 2018-05-11 2021-09-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ フューリンインヒビター

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
EP2478766A3 (en) 2007-05-09 2012-08-15 Burnham Institute for Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
CN107441094B (zh) * 2017-08-08 2020-05-22 南方医科大学 尼罗替尼作为治疗登革病毒感染的药物及其制药用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150051138A1 (en) * 2012-03-16 2015-02-19 Sanford-Burnham Medical Research Institute Inhibitors of furin and other pro-protein convertases
WO2014152716A1 (en) * 2013-03-15 2014-09-25 President And Fellows Of Harvard College Substituted heterocyclic compounds for treating or preventing viral infections
JP2021523941A (ja) * 2018-05-11 2021-09-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ フューリンインヒビター

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCHEMICAL PHARMACOLOGY, vol. 96, no. 2, JPN6024045336, 2015, pages 107 - 118, ISSN: 0005456275 *
CLINICAL AND TRANSLATIONAL IMMUNOLOGY, vol. Vol.8, e1073, JPN6024045337, August 2019 (2019-08-01), pages 1 - 19, ISSN: 0005456276 *

Also Published As

Publication number Publication date
US20230011571A1 (en) 2023-01-12
CA3157892A1 (en) 2021-05-20
KR20220104744A (ko) 2022-07-26
EP4058021A1 (en) 2022-09-21
WO2021097009A1 (en) 2021-05-20
CN114929220A (zh) 2022-08-19
AU2020382819A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
AU2018386298B2 (en) Inhibitors of fibroblast activation protein
TWI864048B (zh) 抗病毒雜環化合物、其醫藥組成物及其用途
JP6804524B2 (ja) Ｉｒａｋ４モジュレーターとしての二環式縮合ヘテロアリールまたはアリール化合物
CN115215886B (zh) 作为内体Toll样受体抑制剂的化合物及组合物
CN110088099B (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法
AU2025242182A1 (en) Compounds and methods for the targeted degradation of androgen receptor
AU2020256220A1 (en) CDK2/5 degraders and uses thereof
CN106573936B (zh) 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物和其作为MGLUR2受体的负性别构调节物的用途
TW201811795A (zh) 胺基－吡咯并嘧啶酮化合物及其用途
CN105566321B (zh) 杂芳化合物及其在药物中的应用
TW200838517A (en) Compounds useful as protein kinases inhibitors
CN103415521A (zh) 用作β分泌酶（BACE）抑制剂的3,4-二氢-吡咯并[1,2-a]吡嗪-1-基胺衍生物
CA2828478A1 (en) Serine/threonine kinase inhibitors
TW200817403A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN110291090A (zh) 作为新型jak激酶抑制剂的双环胺
CA3214240A1 (en) Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
TW202336011A (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
CN117355523A (zh) 血浆激肽释放酶的多环抑制剂
IL273237B1 (en) New heterocyclic compounds as mglur7 modulators
JP2023503852A (ja) 感染症を処置するための低分子フーリン阻害剤
CN117396469A (zh) 血浆激肽释放酶的抑制剂
CN108137608B (zh) Janus激酶1选择性抑制剂及其药物用途
JP2022526979A (ja) Ａｔｐ競合性ａｋｔ阻害剤ｇｄｃ－００６８とｅ３リガーゼリガンドとの結合によるａｋｔの分解および使用方法
WO2024211834A1 (en) Biaryl derivatives and related uses
TWI894448B (zh) Ctla-4小分子降解劑及其應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250226